2. Immunology/Inflammation Apoptosis Metabolic Enzyme/Protease Membrane Transporter/Ion Channel
  3. NO Synthase COX Caspase HIF/HIF Prolyl-Hydroxylase ASCT
  4. Agnuside

Agnuside is used in the study of asthma, inflammation, and angiogenic diseases. Agnuside is an orally active compound that can be extracted from Vitex negundo.

For research use only. We do not sell to patients.

Agnuside Chemical Structure

Agnuside Chemical Structure

CAS No. : 11027-63-7

Size Price Stock Quantity
1 mg USD 50 In-stock
5 mg USD 135 In-stock
10 mg USD 220 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Agnuside:

Agnuside Related Antibodies

Top Publications Citing Use of Products

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

View All COX Isoform Specific Products:

View All Isoforms
COX COX-1 COX-2 COX-3

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

View All HIF/HIF Prolyl-Hydroxylase Isoform Specific Products:

View All Isoforms
HIF-1α HIF

View All ASCT Isoform Specific Products:

View All Isoforms
ASCT1 ASCT2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Agnuside is used in the study of asthma, inflammation, and angiogenic diseases. Agnuside is an orally active compound that can be extracted from Vitex negundo[1][2][3][4].

IC50 & Target

EP

 

Cellular Effect
Cell Line Type Value Description References
HUVEC EC50
1.376 μg/mL
Compound: Agnuside
Pro-angiogenic activity in HUVEC assessed as increase in cell proliferation after 96 hrs by DAPI staining-based spectrofluorometric analysis
Pro-angiogenic activity in HUVEC assessed as increase in cell proliferation after 96 hrs by DAPI staining-based spectrofluorometric analysis
[PMID: 30340142]
In Vitro

Agnuside (100 μM, 12-20 h) decreases the expression of iNOS, COX-2 and IL-8 proteins, and has anti-inflammatory effect in RAW264.7 and HT-29 cells stimulated by LPS (1 μg/mL/100 ng/mL) [2].
Agnuside (0.1-2500 ng/mL, 20-96 h) promotes angiogenesis in HUVEC by promoting cell proliferation (EC50= 1.376 µg/mL) in a time- and dose-dependent manner[3].
Agnuside (3 μM, 4 h) significantly reduces the levels of caspase-1, ASC, NLRP3, HIF-1α, IL-1β and IL-18 to inhibit inflammation in LPS (10 μg/ml) -stimulated fibroblast-like synoviocytes (FLSs)[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Agnuside Related Antibodies
In Vivo

Agnuside (6.25 mg/kg; Oral administration; Single dose) reduces the levels of allergic inflammatory mediators in a dose-dependent manner and can inhibit allergic inflammation in Balb/C mice[1]. Agnuside (6.25 mg/kg; Oral administration; Single dose) can inhibit autophagy in allergic asthma in Balb/C mice [1]. Agnuside (6.25 mg/kg; Oral administration; single dose) can reduce synovitis and fibrosis in knee osteoarthritis (KOA) in MIA-induced KOA mice[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Balb/C female mice model [1]
Dosage: 30 mg/kg, 60 mg/kg
Administration: Oral gavage (p.o.); Single dose;
Result: Decreased the expression of LC3B and increased the expression of Beclin1/p62 (LC3B and Beclin1/p62 are autophagy markers).
Decreased the levels of IgE and IL-4/ IL-10 in a dose-dependent manner.( IgE and IL-4/ IL-10 are allergic inflammatory mediators)
Animal Model: KAO rat model[4]
Dosage: 6.25 mg Monosodium iodoacetate (MIA): 1 mg
Administration: Oral gavage (p.o.); Single dose
Result: Alleviated the degree of local hypoxia in the synovial tissue of rats and significantly reduced the level of pro-fibrotic substances in the synovial tissue.
Inhibited the accumulation of HIF-1α and activation of NLRP3 inflammasome.
Molecular Weight

466.44

Formula

C22H26O11
CAS No.
Appearance

Solid

Color

White to yellow

SMILES

OC[C@H]([C@@H](O)[C@H](O)[C@H]1O)O[C@@]1([H])O[C@H]2[C@@]3([H])[C@](C=CO2)([H])[C@H](O)C=C3COC(C4=CC=C(O)C=C4)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (214.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.1439 mL 10.7195 mL 21.4390 mL
5 mM 0.4288 mL 2.1439 mL 4.2878 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (5.36 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.1439 mL 10.7195 mL 21.4390 mL 53.5975 mL
5 mM 0.4288 mL 2.1439 mL 4.2878 mL 10.7195 mL
10 mM 0.2144 mL 1.0719 mL 2.1439 mL 5.3597 mL
15 mM 0.1429 mL 0.7146 mL 1.4293 mL 3.5732 mL
20 mM 0.1072 mL 0.5360 mL 1.0719 mL 2.6799 mL
25 mM 0.0858 mL 0.4288 mL 0.8576 mL 2.1439 mL
30 mM 0.0715 mL 0.3573 mL 0.7146 mL 1.7866 mL
40 mM 0.0536 mL 0.2680 mL 0.5360 mL 1.3399 mL
50 mM 0.0429 mL 0.2144 mL 0.4288 mL 1.0719 mL
60 mM 0.0357 mL 0.1787 mL 0.3573 mL 0.8933 mL
80 mM 0.0268 mL 0.1340 mL 0.2680 mL 0.6700 mL
100 mM 0.0214 mL 0.1072 mL 0.2144 mL 0.5360 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Agnuside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Agnuside11027-63-7AgnosideNO SynthaseCOXCaspaseHIF/HIF Prolyl-HydroxylaseASCTNitric oxide synthasesNOSCyclooxygenaseHypoxia-inducible factorsHIFsHIF-PHAlanine/serine/cysteine transporter| RAW264.7HUVECHT-29Balb/CKAOArthritisAngiogenesisAntioxidantAsthmaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Agnuside
Cat. No.:
HY-N2518
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.